U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H14Cl2N2.HNO3
Molecular Weight 392.236
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EBERCONAZOLE NITRATE

SMILES

O[N+]([O-])=O.ClC1=CC(Cl)=C2C(N3C=CN=C3)C4=CC=CC=C4CCC2=C1

InChI

InChIKey=DPHMSVRBAXJSPF-UHFFFAOYSA-N
InChI=1S/C18H14Cl2N2.HNO3/c19-14-9-13-6-5-12-3-1-2-4-15(12)18(17(13)16(20)10-14)22-8-7-21-11-22;2-1(3)4/h1-4,7-11,18H,5-6H2;(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula C18H14Cl2N2
Molecular Weight 329.223
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula HNO3
Molecular Weight 63.0128
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Eberconazole is an antifungal drug with broad antimicrobial spectrum of activity. The drug was developed and approved in Spain (Ebernet 1% cream) for the treatment of tinea. Eberconazole exerts fungicidal or fungistatic activity depending on concentration, being fungicidal at higher concentration and fungistatic at lower concentrations. Eberconazole prevents fungal growth by inhibiting ergosterol synthesis, an essential component of the fungal cytoplasmic membrane leading to structural and functional changes. It prevents the fungal ergosterol synthesis by inhibiting lanosterol 14alpha-demethylase enzyme that is responsible for the formation of 14 alpha-methylsterols (precursor of ergosterols).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Lanosterol 14-alpha demethylase
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
EBERNET

Approved Use

EBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis.

Launch Date

2004
Curative
EBERNET

Approved Use

EBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis.

Launch Date

2004
Curative
EBERNET

Approved Use

EBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis.

Launch Date

2004
Doses

Doses

DosePopulationAdverse events​
2 % 2 times / day multiple, topical
Highest studied dose
Dose: 2 %, 2 times / day
Route: topical
Route: multiple
Dose: 2 %, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: Burning skin, Itching...
Other AEs:
Burning skin (grade 1, 6.7%)
Itching (grade 1, 6.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Burning skin grade 1, 6.7%
2 % 2 times / day multiple, topical
Highest studied dose
Dose: 2 %, 2 times / day
Route: topical
Route: multiple
Dose: 2 %, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Itching grade 1, 6.7%
2 % 2 times / day multiple, topical
Highest studied dose
Dose: 2 %, 2 times / day
Route: topical
Route: multiple
Dose: 2 %, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Eberconazole--pharmacological and clinical review.
2012-03-17
Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and influence of culture medium.
2005-05
In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes.
2003-11
In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole.
1999-05
[Topical treatment with eberconazole of the experimental guinea pig cutaneous candidosis.].
1999-03
Patents

Sample Use Guides

Eberconazole (Ebernet 1% cream) should be applied twice a day for 4 weeks. The cream should be applied in sufficient quantity to cover the lesion and surroundings, and should be distributed with the aid of a light massage.
Route of Administration: Topical
Antifungal activity of eberconazole was tested against 200 strains of dermatophytes. The MIC50 values were 0.06 ug/ml (E. floccosum, M. audouinii, M. canis, M. gypseum, T. ajelloi, T. violaceum), 0.03 ug/ml (M. ferrugineum, M. fulvum, T. balcaneum), 0.25 ug/ml (T. erinacei), 0.125 ug/ml (T. interdigitale, T. mentagrophytes, T. rubrum, T. simii, T. tonsurans).
Substance Class Chemical
Created
by admin
on Wed Apr 02 13:54:33 GMT 2025
Edited
by admin
on Wed Apr 02 13:54:33 GMT 2025
Record UNII
LSL8E59V2V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
1-(2,4-DICHLORO-10,11-DIHYDRO-5H-DIBENZO(A,D)(7)ANNULEN-5-YL)-1H-IMIDAZOLE NITRATE (1:1)
Preferred Name English
EBERCONAZOLE NITRATE
Common Name English
1H-IMIDAZOLE, 1-(2,4-DICHLORO-10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)-, NITRATE (1:1)
Common Name English
1H-IMIDAZOLE, 1-(2,4-DICHLORO-10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)-, MONONITRATE
Common Name English
1-(4,6-DICHLORO-2-TRICYCLO(9.4.0.03,8)PENTADECA-1(15),3(8),4,6,11,13-HEXAENYL)IMIDAZOLE;NITRIC ACID
Common Name English
Code System Code Type Description
SMS_ID
100000170416
Created by admin on Wed Apr 02 13:54:33 GMT 2025 , Edited by admin on Wed Apr 02 13:54:33 GMT 2025
PRIMARY
CAS
130104-32-4
Created by admin on Wed Apr 02 13:54:33 GMT 2025 , Edited by admin on Wed Apr 02 13:54:33 GMT 2025
PRIMARY
FDA UNII
LSL8E59V2V
Created by admin on Wed Apr 02 13:54:33 GMT 2025 , Edited by admin on Wed Apr 02 13:54:33 GMT 2025
PRIMARY
PUBCHEM
179851
Created by admin on Wed Apr 02 13:54:33 GMT 2025 , Edited by admin on Wed Apr 02 13:54:33 GMT 2025
PRIMARY
EPA CompTox
DTXSID80926597
Created by admin on Wed Apr 02 13:54:33 GMT 2025 , Edited by admin on Wed Apr 02 13:54:33 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY